Your browser doesn't support javascript.
loading
The role of antimicrobial prophylaxis in patients with head and neck cancer undergoing chemoradiation.
Jaeger, Alina T; Connelly, James E; Jin, Ruyun; Jacobson, Samuel N; Leidner, Rom S.
Afiliação
  • Jaeger AT; University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Connelly JE; Providence Health and Services, Providence St. Vincent Medical Center, Portland, OR, USA.
  • Jin R; Providence Health and Services, Providence Portland Medical Center, Portland, OR, USA.
  • Jacobson SN; Providence Health and Services, Providence St. Vincent Medical Center, Portland, OR, USA.
  • Leidner RS; Providence Health and Services, Providence Portland Medical Center, Portland, OR, USA.
J Oncol Pharm Pract ; 26(3): 580-586, 2020 Apr.
Article em En | MEDLINE | ID: mdl-31288635
BACKGROUND/OBJECTIVE: National guidelines do not recommend the routine use of antimicrobial prophylaxis in patients with solid tumors, yet prophylactic agents are still sometimes prescribed for head and neck cancer patients. The purpose of this study is to determine the effect of prophylactic antimicrobials on the incidence of infection in patients undergoing chemoradiation for head and neck cancer. METHODS: Between 2013 and 2016, patients receiving chemoradiation for head and neck cancer at three outpatient oncology clinics were identified by retrospective review. Cohorts were based on administration or absence of prophylactic antimicrobials. The primary outcome of this study was incidence of infection. Secondary outcomes included incidence of hospitalization and length of hospital stay. RESULTS: Seventy-seven patients were analyzed, 47% (n = 36) were not prescribed antimicrobial prophylaxis and 53% (n = 41) were prescribed prophylaxis. Infection occurred in 31 patients in the no prophylaxis cohort and in 34 patients in the prophylaxis cohort (86.1% vs. 82.9%, p = 0.945). Twenty patients in the no prophylaxis cohort were hospitalized versus 16 patients in the prophylaxis cohort (p = 0.222). The average length of hospital stay was 6 days in the no prophylaxis cohort and 10.6 days in the prophylaxis cohort (p = 0.007). CONCLUSION: The use of antimicrobial prophylaxis did not significantly impact the incidence of infection when compared to patients who were not prescribed prophylaxis. There was no difference in the incidence of hospitalization, however, the patients in the prescribed prophylactic group had longer length of hospital stay.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiorradioterapia / Neoplasias de Cabeça e Pescoço / Anti-Infecciosos Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiorradioterapia / Neoplasias de Cabeça e Pescoço / Anti-Infecciosos Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2020 Tipo de documento: Article